Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397319 | 1.00 | MAPT (0.48) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL5486633 | 0.82 | MAPT (0.42) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL5486629 | 0.82 | MAPT (0.42) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL6773082 | 0.81 | MAPT (0.43) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL12609501 | 0.80 | MAPT (0.46) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL18019504 | 0.78 | HTT (0.54) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL398342 | 0.78 | PTPRC (0.50) | MAPTALDH1A1RAB9ANPC1GAA | |
| SCHEMBL14129177 | 0.77 | MAPT (0.40) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL14138184 | 0.77 | MAPT (0.40) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL5210156 | 0.76 | PTPRC (0.44) | MAPTSMN1; SMN2L3MBTL1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2021-04-20 | — | — | US | disclosed |
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-10-15 | — | — | US | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2020-08-11 | — | — | US | disclosed |
| CN-107652303-B | Novel thienopyrimidine derivatives, preparation method and therapeutic use thereof | 赛诺菲 | 2020-08-04 | — | — | CN | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200078370-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-03-12 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190151330-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2019-05-23 | — | — | US | disclosed |
| EP-1974212-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | Vertex Pharmaceuticals Incorporated (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| US-6191146-B1 | BACTERICIDES, FUNGICIDES, VIRICIDES | SMITHKLINE BEECHAM CORPORATION | 2001-02-20 | — | — | US | disclosed |
| EP-0866700-A4 | HEMOREGULATORY COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0866700-A1 | HEMOREGULATORY COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997017958-A1 | HEMOREGULATORY COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | MAPT 4269/4885SMN1; SMN2 4837/4885L3MBTL1 3552/4885 |
| US-20200078370-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | MAPT 4293/4885SMN1; SMN2 2135/4885L3MBTL1 4615/4885 |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | MAPT 4314/4885SMN1; SMN2 1970/4885L3MBTL1 4539/4885 |
| US-20190151330-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | MAPT 4293/4885SMN1; SMN2 2135/4885L3MBTL1 4615/4885 |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | MAPT 4120/4885SMN1; SMN2 2461/4885L3MBTL1 4523/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | MAPT 4775/4885SMN1; SMN2 4860/4885L3MBTL1 3929/4885 |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | MAPT 4153/4885SMN1; SMN2 2323/4885L3MBTL1 4432/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | MAPT 4847/4885SMN1; SMN2 4740/4885L3MBTL1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.